153 related articles for article (PubMed ID: 9808483)
41. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover].
Celi M; Balducci S; Schiappoli A; Caliumi C; Petramala L; Cerci S; Cotesta D; D'Erasmo E; Letizia C
Ann Ital Med Int; 2003; 18(2):89-98. PubMed ID: 12886826
[TBL] [Abstract][Full Text] [Related]
42. A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis.
Floreani A; Carderi I; Ferrara F; Rizzotto ER; Luisetto G; Camozzi V; Baldo V
Dig Liver Dis; 2007 Jun; 39(6):544-8. PubMed ID: 17416215
[TBL] [Abstract][Full Text] [Related]
43. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease.
Shane E; Silverberg SJ; Donovan D; Papadopoulos A; Staron RB; Addesso V; Jorgesen B; McGregor C; Schulman L
Am J Med; 1996 Sep; 101(3):262-9. PubMed ID: 8873487
[TBL] [Abstract][Full Text] [Related]
44. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
Finkelstein JS; Hayes A; Hunzelman JL; Wyland JJ; Lee H; Neer RM
N Engl J Med; 2003 Sep; 349(13):1216-26. PubMed ID: 14500805
[TBL] [Abstract][Full Text] [Related]
45. Prevalence of osteoporosis, osteopenia, and vertebral fractures in long-term renal transplant recipients.
Marcén R; Caballero C; Uriol O; Fernández A; Villafruela JJ; Pascual J; Martins J; Rodriguez N; Burgos FJ; Ortuño J
Transplant Proc; 2007 Sep; 39(7):2256-8. PubMed ID: 17889156
[TBL] [Abstract][Full Text] [Related]
46. Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass.
Filipponi P; Cristallini S; Policani G; Schifini MF; Casciari C; Garinei P
Bone; 2000 Mar; 26(3):269-74. PubMed ID: 10710000
[TBL] [Abstract][Full Text] [Related]
47. Loss of bone mineral density in renal transplantation recipients.
Unal A; Kocyigit I; Sipahioglu MH; Tokgoz B; Kavuncuoglu F; Oymak O; Utas C
Transplant Proc; 2010 Nov; 42(9):3550-3. PubMed ID: 21094813
[TBL] [Abstract][Full Text] [Related]
48. Treatment of osteoporosis with TheraCyte-encapsulated parathyroid cells: a study in a rat model.
Chou FF; Huang SC; Chen SS; Wang PW; Huang PH; Lu KY
Osteoporos Int; 2006; 17(6):936-41. PubMed ID: 16596462
[TBL] [Abstract][Full Text] [Related]
49. Ibandronate in stable renal transplant recipients with low bone mineral density on long-term follow-up.
Tillmann FP; Schmitz M; Jäger M; Krauspe R; Rump LC
Int Urol Nephrol; 2016 Feb; 48(2):279-86. PubMed ID: 26498632
[TBL] [Abstract][Full Text] [Related]
50. Bisphosphonates are effective prophylactic of early bone loss after renal transplantation.
Nowacka-Cieciura E; Cieciura T; Baczkowska T; Kozińska-Przybył O; Tronina O; Chudziński W; Pacholczyk M; Durlik M
Transplant Proc; 2006; 38(1):165-7. PubMed ID: 16504693
[TBL] [Abstract][Full Text] [Related]
51. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial.
Grey AB; Stapleton JP; Evans MC; Tatnell MA; Reid IR
Ann Intern Med; 1996 Sep; 125(5):360-8. PubMed ID: 8702086
[TBL] [Abstract][Full Text] [Related]
52. [Markers of calcium--phosphate metabolism and bones alterations in long term kidney transplant patients].
Spiechowicz U; Kokot F; Wiecek A
Przegl Lek; 2003; 60(11):690-4. PubMed ID: 15058034
[TBL] [Abstract][Full Text] [Related]
53. Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients.
Ersoy FF; Passadakis SP; Tam P; Memmos ED; Katopodis PK; Ozener C; Akçiçek F; Camsari T; Ateş K; Ataman R; Vlachojannis JG; Dombros AN; Utaş C; Akpolat T; Bozfakioğlu S; Wu G; Karayaylali I; Arinsoy T; Stathakis PC; Yavuz M; Tsakiris JD; Dimitriades CA; Yilmaz ME; Gültekin M; Karayalçin B; Yardimsever M; Oreopoulos DG
J Bone Miner Metab; 2006; 24(1):79-86. PubMed ID: 16369903
[TBL] [Abstract][Full Text] [Related]
54. "Twice-a-month" clodronate 200 mg IM: a new dosing regimen and improved therapy adherence in the treatment of postmenopausal osteoporosis.
Muratore M; Quarta L; Calcagnile F; Quarta E
Adv Ther; 2010 May; 27(5):314-20. PubMed ID: 20526703
[TBL] [Abstract][Full Text] [Related]
55. Loss of regional bone mineral density in the first 12 months following renal transplantation.
Almond MK; Kwan JT; Evans K; Cunningham J
Nephron; 1994; 66(1):52-7. PubMed ID: 8107953
[TBL] [Abstract][Full Text] [Related]
56. The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study.
Tóth E; Csupor E; Mészáros S; Ferencz V; Németh L; McCloskey EV; Horváth C
Bone; 2005 Jan; 36(1):47-51. PubMed ID: 15664001
[TBL] [Abstract][Full Text] [Related]
57. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
Struys A; Snelder AA; Mulder H
Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
[TBL] [Abstract][Full Text] [Related]
58. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
59. Short-term effects of a chicken egg shell powder enriched dairy-based products on bone mineral density in persons with osteoporosis or osteopenia.
Schaafsma A; Pakan I
Bratisl Lek Listy; 1999 Dec; 100(12):651-6. PubMed ID: 10758743
[TBL] [Abstract][Full Text] [Related]
60. Bone mineral density progression following long-term simultaneous pancreas-kidney transplantation in type-1 diabetes.
Santos Monteiro S; Silva Santos T; Pereira CA; Duarte DB; Silva F; Martins S; Dores J
Ann Endocrinol (Paris); 2023 Aug; 84(4):454-459. PubMed ID: 36931500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
